Forwarding the Limited Review Report from Statutory Auditors and Financial Results for the Quarter and Half Year ended 30.09.2018

Wintac Ltd. manufactures pharmaceuticals.  The Company produces antifungals; anticancer; cardiovascular; corticosterid; and antiemetic drugs; and ophthalmic solutions.

Financial Results For The Half Year Ended 30/09/2018

WINTAC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2018 ,inter alia, to consider and approve Intimation, pursuant to Regulation 29 of the SEBI (LODR) Regulations 2015, is made the the Meeting of the Board of directors of the Company is scheduled on November 12, 2018 for considering unaudited financial results of the Company for the Quarter and Half Year ended 30.09.2018.

Board Meeting Intimation For Board Meeting On November 12, 2018 For Half Year Financial Results.

Pursuant to Regulation 34 of SEBI (LODR) Regulations, Annual Report for the financial year 2017-18 adopted by the Shareholders at the Anuual GeneraL Meeting held on October 27, 2018 is enclosed.

Annual Report For The Financial Year 2017-18

We are submitting the Voting Results for the Resolutions passed by the Shareholders at the Annual General Meeting held on October 27, 2018 alongwith Scrutinizer''s Report.

Shareholder Meeting / Postal Ballot-Scrutinizer''S Report

We are forwarding the Summary of Proceedings of Annual General Meeting of the Company held on October 27, 2018 at 10.00 am at the Registered Office of the Company at Nelamangala, Bangalore.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Wintac Ltd (RCN IN)

Financial Results For The Half Year Ended 30/09/2018

Board Meeting Intimation For Board Meeting On November 12, 2018 For Half Year Financial Results.

Annual Report For The Financial Year 2017-18

Shareholder Meeting / Postal Ballot-Scrutinizer''S Report

Shareholder Meeting / Postal Ballot-Outcome Of Agm

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)